New Jersey Better Educational Savings Trust bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent filing with the SEC. The institutional investor bought 2,000 shares of the life sciences company’s stock, valued at approximately $347,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Walter & Keenan Financial Consulting Co. MI ADV raised its position in Illumina by 1.5% in the second quarter. Walter & Keenan Financial Consulting Co. MI ADV now owns 6,650 shares of the life sciences company’s stock valued at $1,154,000 after buying an additional 100 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in Illumina by 5.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 484,721 shares of the life sciences company’s stock valued at $84,109,000 after buying an additional 24,459 shares in the last quarter. Wetherby Asset Management Inc. raised its position in Illumina by 10.7% in the second quarter. Wetherby Asset Management Inc. now owns 1,733 shares of the life sciences company’s stock valued at $301,000 after buying an additional 167 shares in the last quarter. Trexquant Investment LP purchased a new position in Illumina during the second quarter valued at approximately $607,000. Finally, Global X Management Co. LLC raised its position in Illumina by 84.2% in the second quarter. Global X Management Co. LLC now owns 2,360 shares of the life sciences company’s stock valued at $410,000 after buying an additional 1,079 shares in the last quarter. 93.81% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Illumina, Inc. (NASDAQ ILMN) opened at 194.25 on Friday. The firm’s 50-day moving average is $179.63 and its 200-day moving average is $173.73. The company has a market capitalization of $28.36 billion, a price-to-earnings ratio of 38.97 and a beta of 0.83. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $199.95.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business had revenue of $662 million for the quarter, compared to analysts’ expectations of $642.38 million. During the same period last year, the business earned $0.86 earnings per share. The business’s quarterly revenue was up 10.3% on a year-over-year basis. On average, equities analysts predict that Illumina, Inc. will post $3.65 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “New Jersey Better Educational Savings Trust Buys Shares of 2,000 Illumina, Inc. (ILMN)” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://theolympiareport.com/2017/08/12/new-jersey-better-educational-savings-trust-buys-shares-of-2000-illumina-inc-ilmn.html.

Several equities analysts have commented on the stock. Barclays PLC reissued an “equal weight” rating and issued a $150.00 target price on shares of Illumina in a report on Wednesday. Vetr raised shares of Illumina from a “hold” rating to a “buy” rating and set a $209.78 target price on the stock in a report on Wednesday. Canaccord Genuity raised shares of Illumina from a “hold” rating to a “buy” rating and raised their target price for the company from $170.00 to $215.00 in a report on Monday, August 7th. BidaskClub raised shares of Illumina from a “sell” rating to a “hold” rating in a report on Monday, August 7th. Finally, Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the stock. Illumina has an average rating of “Hold” and an average target price of $177.01.

In other Illumina news, SVP Charles Dadswell sold 1,609 shares of the stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $197.00, for a total transaction of $316,973.00. Following the transaction, the senior vice president now directly owns 9,037 shares in the company, valued at $1,780,289. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jay T. Flatley sold 15,000 shares of the stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $175.53, for a total transaction of $2,632,950.00. Following the transaction, the director now owns 534,176 shares in the company, valued at $93,763,913.28. The disclosure for this sale can be found here. Insiders have sold 134,010 shares of company stock worth $23,946,015 over the last quarter. Company insiders own 1.60% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.